MiMedx Group (NASDAQ:MDXG) Lowered to “Buy” at StockNews.com

StockNews.com downgraded shares of MiMedx Group (NASDAQ:MDXG) from a strong-buy rating to a buy rating in a research note published on Tuesday.

Several other brokerages have also recently commented on MDXG. Cantor Fitzgerald restated an “overweight” rating and set a $11.00 target price on shares of MiMedx Group in a report on Thursday, August 1st. Craig Hallum decreased their price objective on MiMedx Group from $14.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, August 1st. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $12.00.

MiMedx Group Stock Performance

MDXG opened at $5.82 on Tuesday. The company has a market capitalization of $859.06 million, a price-to-earnings ratio of 13.23 and a beta of 1.97. The business’s 50-day moving average price is $6.15 and its two-hundred day moving average price is $6.72. MiMedx Group has a 1 year low of $5.47 and a 1 year high of $9.27. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.85 and a quick ratio of 3.22.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.08. The business had revenue of $87.21 million during the quarter, compared to the consensus estimate of $88.44 million. MiMedx Group had a return on equity of 34.24% and a net margin of 23.63%. Equities analysts expect that MiMedx Group will post 0.26 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Headlands Technologies LLC acquired a new stake in MiMedx Group in the 1st quarter valued at about $27,000. Blue Trust Inc. acquired a new stake in shares of MiMedx Group in the third quarter valued at approximately $30,000. Point72 Asset Management L.P. bought a new position in shares of MiMedx Group during the 2nd quarter worth approximately $40,000. Quest Partners LLC acquired a new position in shares of MiMedx Group during the 2nd quarter worth approximately $81,000. Finally, Entropy Technologies LP bought a new stake in MiMedx Group in the 1st quarter valued at $99,000. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.